Jorge Diaz, MD
Internal Medicine · Pembroke Pines, FLNPI 1205878261
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $17,402 of the $22,727 with a category attached, or 76.6%. Abbott accounts for 79.8% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2024 at $18,756 and has fallen 97.2% since, to $533 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $77.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$18K
- Novo Nordisk$1K
- AstraZeneca$503
- Pfizer$448
- Bayer$292
- Amgen$277
- plus $2K from 30 others
What the payments were for
- Travel & lodging$17,40277%
- Food & beverage$5,32123%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 66 | $18,131 |
| Novo Nordisk | 63 | $1,193 |
| AstraZeneca | 15 | $503 |
| Pfizer | 24 | $448 |
| Bayer | 10 | $292 |
| Amgen(2 entities) | 17 | $277 |
| Avanir Pharmaceuticals, Inc. | 20 | $244 |
| Lilly USA, LLC | 14 | $223 |
| GSK | 7 | $156 |
| Exact Sciences | 6 | $137 |
| Intuitive Surgical | 1 | $129 |
| Idorsia Pharmaceuticals US Inc | 5 | $118 |
| Kowa Pharmaceuticals America, Inc. | 6 | $113 |
| AbbVie(2 entities) | 6 | $89 |
| Novartis | 3 | $63 |
| Radius Health, Inc. | 3 | $62 |
| Dexcom, Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Beone Medicines USA, Inc. | 2 | $43 |
| Clovis Oncology, Inc. | 3 | $43 |
| Greenwich Biosciences, Inc. | 1 | $27 |
| Acerus Pharmaceuticals Corporation | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Tris Pharma Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$16,912
- ABSOLUTE PRO$129
- Da Vinci Surgical System$129
- BREZTRI$125
- Kerendia$105
How this compares
$22,727 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 93 | $120,591 |
| EliquisApixaban | 76 | $96,232 |
| MounjaroTirzepatide | 60 | $75,083 |
| TrulicityDulaglutide | 47 | $65,561 |
| OzempicSemaglutide | 40 | $53,143 |
| ProliaDenosumab | 26 | $44,235 |
| RybelsusSemaglutide | 22 | $39,681 |
| JardianceEmpagliflozin | 33 | $34,428 |
| JanuviaSitagliptin Phosphate | 22 | $32,356 |
| XareltoRivaroxaban | 23 | $23,531 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $19,862 |
| Repatha SureclickEvolocumab | 17 | $18,723 |
| LinzessLinaclotide | 16 | $16,427 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $15,022 |
| VascepaIcosapent Ethyl | 15 | $14,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $223 | $140,643107 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $503 | $132,937104 claims |
| PfizerEliquis, Paxlovid | $448 | $99,09192 claims |
| Novo NordiskOzempic, Rybelsus | $1,193 | $92,82462 claims |
| AmgenProlia | $277 | $44,23526 claims |
| AbbVieLinzess, Creon, Lumigan, Synthroid | $89 | $38,46388 claims |
| Boehringer IngelheimJardiance | $24 | $34,42833 claims |
| Johnson & JohnsonXarelto | $20 | $23,53123 claims |
| GSKTrelegy Ellipta | $156 | $15,02220 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $13,54714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pembroke Pines
- Manuel GonzalezPembroke Pines$37K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.